Form 4: Beam Therapeutics Inc. Executive Granted Stock Options

Amy Simon, Chief Medical Officer of Beam Therapeutics Inc., was granted stock options to purchase 55,000 shares of common stock.

Summary

• Amy Simon, the Chief Medical Officer of Beam Therapeutics Inc., was granted stock options on January 31, 2025.
• The options allow her to purchase 55,000 shares of Beam Therapeutics' common stock at an exercise price of $25.92 per share.
• The stock options vest in equal monthly installments over 48 months, contingent upon her continued service with the company.
• The options expire on January 31, 2035.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral to slightly positive indicator.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing her to contribute to the company's success.
• The vesting schedule encourages long-term commitment from the Chief Medical Officer.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like CRISPR Therapeutics and Editas Medicine also utilize stock options to incentivize their leadership teams.
• The vesting schedule of 48 months is typical for such grants, ensuring long-term commitment.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Medical Officer to drive company performance.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates